Program Overview

The 7th Annual Global Summit on Hematological Malignancies focuses on the clinical and practical changes that will occur over the next five years in Leukemia, Lymphoma and Multiple Myeloma. The program is formatted to foster discussion and debate on the evolution of treatment approaches to hematological malignancies featuring didactic lectures, panel discussions and case presentations over individual patient issues and new approaches designed to overcome these challenges.

Presentations will be given by leading experts in the field of hematological malignancies, who will offer further insight during question-and-answer sessions. In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their abstracts at an evening poster reception. The summit assembles translational researchers, clinical researchers, and key community oncologists to address and discuss the challenges of this rapidly developing area of oncology.

Register now and receive complementary $199 registration.

Summit Faculty



Aaron Goldberg, MD, PhD


Hematologic Oncologist

Memorial Sloan Kettering Cancer Center

New York, NY

Adam Cohen, MD


Director, Myeloma Immunotherapy

Associate Professor of Medicine

University of Pennsylavania

Philiadelphia, PA

Adrian Wiestner, MD, PhD


Senior Investigator

National Institutes of Health

Bethesda, MD

Alexander Perl, MD


Associate Professor

University of Pennsylvania

Philadelphia, PA

Alexey Danilov, MD, PhD


Professor, Department of Hematology & Hematopoietic Cell Transplantation

Associate Director, Toni Stephenson Lymphoma Center

City of Hope

Duarte, CA

Amrita Krishnan, MD


Hematologist - Oncologist

City of Hope

Duarte, CA

Andrew Wei, MD


Adjunct Associate Professor

Monash University

Melbourne, Australia

Andrew Zelenetz, MD, PhD


Medical Oncologist

Medical Director, Quality Informatics

Memorial Sloan Kettering Cancer Center

New York, NY

Anthony Letai, MD, PhD


Professor of Medicine

Dana-Farber Cancer Institute

Boston, MA

Brian Hill, MD, PhD


Assistant Professor

Cleveland Clinic, Case Western Reserve University

Cleveland, OH

Carrie Kitko, MD


Associate Professor of Pediatrics, Hematology/Oncology

Ingram Professorship in Pediatric Oncology, Department of Pediatrics

Medical Director, Pediatric Stem Cell Transplantation Program

Vanderbilt University

Nashville, TN

Charles Schiffer, MD


Professor

Karmanos Cancer Institute

Detroit, MI

Courtney DiNardo, MD, MSCE


Associate Professor

MD Anderson Cancer Center

Houston, TX

Dan DeAngelo, MD, PhD


Chief, Division of Leukemia

Professor of Medicine

Dana-Farber Cancer Institute

Boston, MA

Daniel Pollyea, MD, MS


Associate Professor

UC Health - Anschutz Medical Campus

Aurora, CO

Edward Stadtmauer, MD


Roseman, Tarte, Harrow, and Shaffer Families' President's Distingushed Professor

Section Chief, Hematologic Malignancies

University of Pennsylavania

Philiadelphia, PA

Eunice Wang, MD


Chief, Leukemia Service

Roswell Park Comprehensive Cancer Center

Buffalo, NY

Giovanni Martinelli, MD


Professor

University of Bologna

Verona, Italy

Jeffrey Zonder, MD


Professor

Karmanos Cancer Institute

Detroit, MI

Jennifer Brown, MD, PhD


Professor of Medicine

Director, Chronic Lymphocytic Leukemia Center

Dana-Farber Cancer Institute

Boston, MA

John Byrd, MD


D. Warren Brown Chair of Leukemia Research

Distinguished University Professor of Medicine, Medicinal Chemistry, and Veterinary Biosciences

The Ohio State University Comprehensive Cancer Center

Columbus, OH

John Kuruvilla, MD, FRCPC


Clinician Investigator

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

John Pagel, MD, PhD


Chief of Hematologic Malignancies

Swedish Cancer Institute; University of Washington

Seattle, WA

Keith Stewart, MBChB


Vice President, Cancer

Director of the Princess Margaret Cancer Program

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Kendra Sweet, MD


Assistant Professor

Moffitt Cancer Center

Tampa, FL

Laurie Sehn, MD, MPH


Clinical Assistant Professor

University of British Columbia

Vancouver, BC, Canada

Leo Gordon, MD


Abby and John Friend Professor of Oncology Research Professor of Medicine

Northwestern Medicine

Chicago, IL

Lucy Godley, MD, PhD


Hospira Foundation Professor of Medicine and Human Genetics

University of Chicago

Chicago, IL

Michael Wang, MD


Professor

MD Anderson Cancer Center

Houston, TX

Michael Williams, MD


Byrd S. Leavell Professor of Medicine

Professor of Pathology

University of Virginia Health

Charlottesville, VA

Naval Daver, MD


Associate Professor

MD Anderson Cancer Center

Houston, TX

Naveen Pemmaraju, MD


Associate Professor

MD Anderson Cancer Center

Houston, TX

Nikhil Munshi, MD


Professor of Medicine

Kraft Family Chair

Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center

Senior Physician

Dana-Farber Cancer Institute

Boston, MA

Nina Shah, MD


Associate Professor

UCSF Health

San Francisco, CA

Nina Wagner-Johnston, MD


Director of Lymphoma Drug Development

Associate Professor of Oncology

Johns Hopkins Medicine

Baltimore, MD

Nitin Jain, MD


Associate Professor

MD Anderson Cancer Center

Houston, TX

Noopur Raje, MD


Professor of Medicine

Director of the Center for Multiple Myeloma

Massachusetts General Hospital

Boston, MA

Paul Richardson, MD


RJ Corman Professor of Medicine

Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center

Institute Physician

Dana-Farber Cancer Institute

Boston, MA

Rafael Fonseca, MD


Interim Director of Mayo Clinic Cancer Center

Mayo Clinic Cancer Center

Phoenix, AZ

Ranjana Advani, MD


Saul Rosenberg Professor of Lymphoma

Stanford University

Stanford, CA

Ravi Vij, MD, MBA


Professor

Washington University

St. Louis, MO

Richard Stone, MD


Professor of Medicine

Dana-Farber Cancer Institute

Boston, MA

Sarah Rutherford, MD


Assistant Professor of Medicine

Weill Cornell Medicine

New York, NY

Shaji Kumar, MD


Professor of Medicine

Mayo Clinic Cancer Center

Rochester, MN

Stephen Ansell, MD, PhD


Professor of Medicine

Mayo Clinic Cancer Center

Rochester, MN

Stephen Schuster, MD


Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research

Director, Lymphoma Program

Director, Lymphoma Translational Research

University of Pennsylvania

Philadelphia, PA

Steven Coutre, MD


Director of Hematology Clinic

Stanford University

Stanford, CA

Steven Horwitz, MD


Medical Oncologist

Memorial Sloan Kettering Cancer Center

New York, NY

Steven Treon, MD, PhD


Professor of Medicine

Director, Bing Center for Waldenström's Macroglobulinemia

Senior Physician

Dana-Farber Cancer Institute

Boston, MA

Sundar Jagannath, MBBS


Professor of Medicine

Director of the Center of Excellence for Multiple Myeloma

Mount Sinai Hospital

New York, NY

Tom Martin, MD


Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program

Associate Director, Myeloma Program

UCSF Health

San Francisco, CA

Tycel Phillips, MD


Clinical Associate Professor

University of Michigan

Ann Arbor, MI

Summit Agenda

  • Keynote Presentations

    5:00 PMWelcome and Introductions

    5:15 PMHow My Treatment Paradigm for CLL Will Change Over the Next 5 Years

    Steven Coutre

    5:35 PMWill Chemotherapy Be Used in MCL Over the Next 5 Years?

    Michael Wang

    5:55 PMHow T-cell-based Therapy Will Impact Treatment for DLBCL Over the Next 5 Years

    Andrew Zelenetz

    6:15 PMWhat Comes After BTKi for WM?

    Steven Treon

    6:35 PMQ&A and Panel Discussion (30 minutes)

    7:05 PMHow I Will Cure MM

    Ravi Vij

    7:25 PMHow 2020 Changed My Treatment Paradigm for AML

    Richard Stone

    7:45 PMAre We Moving Away from Chemotherapy in ALL?

    Daniel DeAngelo

    8:05 PMIn 2021, What Is the Unmet Need in CML?

    Charles Schiffer

    8:25 PMQ&A and Panel Discussion (35 minutes)

    9:00 PMSession Concludes

  • Updates in Chronic Lymphocytic Leukemia

    5:00 PMWelcome and Introductions

    5:10 PMRecent Update on the Biology of CLL

    Adrian Wiestner

    5:25 PMLong-term Data on Single-agent BTKi in Frontline CLL

    Brian Hill

    5:40 PMRole of Next-generation BTK Inhibitors in CLL

    Nitin Jain

    5:55 PMPooled Safety Analysis for Acalabrutinib in CLL

    Jennifer Brown

    6:10 PMQ&A and Panel Discussion (20 minutes)

    6:30 PMChemo-free Combinations in R/R CLL

    John Byrd

    6:45 PMMechanisms of Resistance to BTK Inhibitors and Venetoclax in CLL

    Alexey Danilov

    7:00 PMQ&A and Panel Discussion (15 min)

    Update on BTK Inhibitors

    7:15 PMHow to Choose a BTK Inhibitor for R/R MCL

    Michael Williams

    7:30 PMChoosing BTK Inhibitors in WM

    Steven Treon

    7:45 PMEmerging ADC Options for B-cell Lymphoma

    Nina Wagner-Johnston

    8:00 PMQ&A and Panel Discussion (15 min)

    Biotech Showcases

    8:15 PMBiotech Showcase

    8:30 PMBiotech Showcase

    8:45 PMBiotech Showcase

    9:00 PMSession Concludes

  • Updates in Lymphoma

    9:00 AMWelcome and Introductions

    9:10 AMRecent Data for CAR-T in DLBCL

    Leo Gordon

    9:25 AMRecent Data for CAR-T in FL

    David Miklos

    9:40 AMCAR-T Cell Therapy in MCL

    Michael Wang

    9:55 AMQ&A and Panel Discussion (25 min)

    10:20 AMRecent Data and Current Development of EZH2 Inhibitors in FL

    John Pagel

    10:35 AMWhere Do PI3Ki Fit in FL

    Tycel Phillips

    10:50 AMQ&A and Panel Discussion (15 min)

    11:05 AMTreatment of Relapsed DLBCL

    Ranjana Advani

    11:20 AMUpdates on CD20/CD3 Bispecific Antibodies in B-cell Lymphomas

    Sarah Rutherford

    11:35 AMHow to Treat Elderly/Frail DLBCL Patients

    Michael Williams

    11:50 AMQ&A and Panel Discussion (15 min)

    12:05 PMAn Update on Hodgkin's Disease

    John Kuruvilla

    12:20 PMNew Treatment Options for Patients with T-cell NHL

    Steven Horwitz

    12:35 PMQ&A and Panel Discussion (25 min)

    1:00 PMSession Concludes

    Updates on Multiple Myeloma

    5:00 PMWelcome and Introductions

    5:10 PMWhen Do I Treat Smoldering Myeloma?

    Amrita Krishnan

    5:25 PMWhat Should Be the New Frontline Treatment for MM in 2021?

    Keith Stewart

    5:40 PMADC Treatment in R/R Myeloma

    Adam Cohen

    5:55 PMQ&A and Panel Discussion (15 min)

    6:10 PMApproaching Treatment Failure in 2021: Unique Challenges

    Rafael Fonseca

    6:25 PMRole of CAR-T Therapy in Triple-class Refractory MM

    Edward Stadtmauer

    6:40 PMNext-generation CAR-T Therapy for MM

    Nina Shah

    6:55 PMQ&A and Panel Discussion (15 min)

    7:10 PMUnderstanding Daratumumab's Impact on Outcome in MM

    Sundar Jagannath

    7:25 PMWhat Role Will Isatuximab Play in R/R MM?

    Thomas Martin

    7:40 PMOptimizing BCMA Targeting in MM

    Noopur Raje

    7:55 PMQ&A and Panel Discussion (15 min)

    8:10 PMWhen to Use Selinexor in R/R MM

    Paul Richardson

    8:25 PMNovel drugs for Treatment of Amyloidosis

    Jeffrey Zonder

    8:40 PMQ&A and Panel Discussion (20 min)

    9:00 PMSession Concludes

  • Updates in Acute Leukemia

    9:00 AMWelcome and Introductions

    9:10 AMUnderstanding the Clinical Significance of Mutational Overlap in AML

    Alexander Perl

    9:25 AMGenomics of Inherited AML

    Lucy Godley

    9:40 AMBH2 Mimetic Proteins in AML

    Anthony Letai

    9:55 AMQ&A and Panel Discussion (15 min)

    10:10 AMHow to Choose Appropriate Induction Therapy for Poor-risk AML

    Eunice Wang

    10:25 AMManagement of Secondary AML

    Kendra Sweet

    10:40 AMMaintenance Therapy in AML

    Giovanni Martinelli

    10:55 AMQ&A and Panel Discussion (15 min)

    11:10 AMCombinations Therapies for FLT3 Mutant AML

    Aaron Goldberg

    11:25 AMFuture Role of IDH1/2 Inhibitors

    Daniel Pollyea

    11:40 AMQ&A and Panel Discussion (15 min)

    11:55 AMVenetoclax in AML, Current Status

    Andrew Wei

    12:10 PMVenetoclax Combinations in AML

    Courtney DiNardo

    12:25 PMQ&A and Panel Discussion (20 min)

    Biotech Showcases

    12:45 PMNovel Approaches for Chronic GVHD

    Carrie Kitko

    1:00 PMIRAK4 Inhibition in AML

    Robert Martell

    1:15 PMTamibarotene in AML/MDS

    David Roth

    1:30 PMSession Concludes

    New Drugs in Hematology

    5:00 PMWelcome and Introductions

    5:10 PMOptimal Sequencing of Therapy for Triple-class Refractory MM

    Paul Richardson

    5:25 PMTargets in Development for MM

    Nikhil Munshi

    5:40 PMThe Emerging Potential for Venetoclax in Multiple Myeloma

    Shaji Kumar

    5:55 PMQ&A and Panel Discussion (20 min)

    New Drugs in MDS/MPN

    6:15 PMCD123-Targeting ADC Monotherapy for BPDCN

    Naveen Pemmaraju

    6:30 PMCheckpoint Inhibitors for AML (CD47, CD70, TIM-3, etc.)

    Naval Daver

    6:45 PMNew Drugs for MDS

    Richard Stone

    7:00 PMQ&A and Panel Discussion (15 min)

    Nonmalignant Hematology

    7:15 PMNovel Agents for Anemia

    7:30 PMNovel Agents for Thrombocytopenia

    7:45 PMNovel Agents for Sickle Cell Disease

    8:00 PMNovel Agents for Thalassemia

    Biotech Showcase

    8:15 PMBiotech Showcase

    8:30 PMBiotech Showcase

    8:45 PMBiotech Showcase

    9:00 PMSession Concludes

Attendance Benefits

  • Attending meeting in comfort of your home
  • Personalize Audio and Video Networking with Peers
  • Participate in discussion and debate surrounding the field of hematological malignancies
  • Learning about new agents and interact with Industry


Virtual Presence

Welcome Lobby
Networking Lounge

Keynote and Sessions

  • Easy and interactive presentations
  • Live Questions and Answers by KOL and Faculty
  • Discussion based group meetings
  • OnDemand access to all sessions

Networking and Resources

  • Private Video and Text conversation with Participants
  • Virtual networking lounge and Expo Hall with industry booths
  • Virtual Poster sessions and interact with presenter
  • Virtual briefcase to bookmark, access and download resources

Dava Oncology – three divisions, one focus

dava oncology logo
omi logo
one-oncology logo

Contact Us